This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Concentra Group Holdings Parent, Inc. (CON) and Palvella Therapeutics (PVLA)

Tipranks - Tipranks - Thu Jul 2, 4:54AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bio-Techne (TECH), Concentra Group Holdings Parent, Inc. (CON) and Palvella Therapeutics (PVLA).

4th of July Sale - 70% Off

Bio-Techne (TECH)

TD Cowen analyst Kyle Boucher downgraded Bio-Techne to Hold yesterday and set a price target of $73.00. The company’s shares closed last Tuesday at $70.65.

According to TipRanks.com, Boucher is a 4-star analyst with an average return of 23.4% and a 90.9% success rate. Boucher covers the Healthcare sector, focusing on stocks such as Standard BioTools, Myriad Genetics, and Bruker. ;'>

Bio-Techne has an analyst consensus of Hold, with a price target consensus of $66.09, which is a -6.7% downside from current levels. In a report issued on June 25, Leerink Partners also downgraded the stock to Hold with a $73.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Concentra Group Holdings Parent, Inc. (CON)

Concentra Group Holdings Parent, Inc. received a Buy rating from William Blair analyst Jared Haase today. The company’s shares closed last Tuesday at $29.75.

According to TipRanks.com, Haase is a 4-star analyst with an average return of 17.8% and a 69.6% success rate. Haase covers the Healthcare sector, focusing on stocks such as BrightSpring Health Services, Inc., Aveanna Healthcare Holdings, and Definitive Healthcare Corp. ;'>

Currently, the analyst consensus on Concentra Group Holdings Parent, Inc. is a Strong Buy with an average price target of $32.00, which is an 8.8% upside from current levels. In a report issued on June 16, TipRanks – PerPlexity also reiterated a Buy rating on the stock with a $33.00 price target.

Palvella Therapeutics (PVLA)

Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Palvella Therapeutics today and set a price target of $240.00. The company’s shares closed last Tuesday at $152.82.

According to TipRanks.com, Suvannavejh is a 5-star analyst with an average return of 21.5% and a 50.4% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Amylyx Pharmaceuticals Inc, and Neumora Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Palvella Therapeutics with a $235.40 average price target, representing a 52.7% upside. In a report issued on June 22, Craig-Hallum also reiterated a Buy rating on the stock with a $205.00 price target.

Read More on TECH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).